The U.S. therapeutic plasma exchange (TPE) market by indication broadly segmented into neurological disorders, hematology disorders, renal disorders, autoimmune disorders, metabolic disorders. Report analyzes therapeutic plasma exchange market by indication, total number of therapeutic plasma exchange procedures performed, number of patients treated with therapeutic plasma exchange in U.S.
- Agency -.
Complete report on U.S. Therapeutic Plasma Exchange Market spread across 91 Pages and Supported with 55 Tables and 10 Figures is now available at www.rnrmarketresearch.com/us-thera…arket-report.html
The U.S. therapeutic plasma exchange (TPE) market by indication estimated to reach USD 260.0 million by 2021, growing at a CAGR of 11% to 12% during forecast period (2016 to 2021). Rising incidences of blood disorders and chronic diseases; rapid increase in aging population; and increasing adoption of therapeutic plasma exchange in rare neurological, hematology, and autoimmune disorders are key factors driving therapeutic plasma exchange market in U.S.
- Therapeutic Plasma Exchange Product Manufacturers
- Group Purchase Organizations (GPOs)
- OEM Manufacturers
- Hospitals and Clinics
- Blood Centers
- Distributors of TPE Products
- Healthcare Institutions
- Research Institutes
- Market Research and Consulting Firms
- Venture Capitalists and Investors
Therapeutic plasma exchange removes plasma components from blood.
- Agency -.
The growing prevalence of neurological diseases; increasing clinical response rate for therapeutic plasma exchange in Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and myasthenia gravis; and growing prevalence of multiple sclerosis in the U.S. are driving the growth in this market segment.
1 Objectives and Scope
2 Research Methodology
3 Market Estimation Methodology
4 Primary Research Methodology
5 Primary Respondent Profile
The major players in the U.S. TPE market are Haemonetics Corporation (U.S.), Fresenius Medical Care (Germany), Terumo BCT, Inc. (U.S.), Baxter International Inc.
(U.S.), Asahi Kasei Medical Co., Ltd. (Japan), Kawasumi Laboratories Inc.
(Japan), B. Braun Melsungen AG (Germany), and HemaCare Corporation (U.S.).
Scope of the Report
Therapeutic plasma exchange resembles dialysis but, in addition, can remove protein-bound toxic substances. A one-volume exchange removes about 66% of such components.
Due to this factor, the awareness among physicians is growing, hence therapeutic plasma exchange is increasingly being adopted in the treatment of rare diseases.
This research report categorizes the U.S. therapeutic plasma exchange market on the basis of indication.
The report also provides information on the total number of patients undergoing TPE procedures, average number of procedures per patient, and total number of TPE procedures performed in the U.S. (2015).
Category: Market Research Publishers and RetailersCompany profile: RnRMarketResearch.com is an online database of market research reports offers in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
For more information: